Search Result

Results for "

multiple system atrophy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (3) Endogenous Metabolite (2) Fluorescent Dye (1) Interleukin Related (1) NF-κB (1) NOD-like Receptor (NLR) (1) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (2) α-synuclein (4)
By Research Areas:	Cancer (2) Cardiovascular Disease (3) Metabolic Disease (3) Neurological Disease (8)

Inhibitors & Agonists

Natural
Products

Targets Recommended: Complement System

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160116

α-Synuclein aggregate binder 1	Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with ¹⁸F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .

HY-N0698

Crocin II	Endogenous Metabolite α-synuclein	Neurological Disease Cancer
Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers .

HY-B1435

Moxisylyte hydrochloride Thymoxamine hydrochloride	Adrenergic Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Moxisylyte (Thymoxamine) hydrochloride is a selective α₁A-adrenergic receptor antagonist. Moxisylyte hydrochloride competitively antagonizes the activation mediated by norepinephrine. Moxisylyte hydrochloride relaxes penile cavernous smooth muscle and aids erectile function. Moxisylyte hydrochloride is applicable to research related to erectile dysfunction and multiple system atrophy .

HY-B1435A

Moxisylyte Thymoxamine	Adrenergic Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Moxisylyte (Thymoxamine) is a selective α₁A-adrenergic receptor antagonist. Moxisylyte competitively antagonizes the activation mediated by norepinephrine. Moxisylyte relaxes penile cavernous smooth muscle and aids erectile function. Moxisylyte is applicable to research related to erectile dysfunction and multiple system atrophy .

HY-N0698R

Crocin II (Standard)	Reference Standards Endogenous Metabolite α-synuclein	Neurological Disease Cancer
Crocin II (Standard) is the analytical standard of Crocin II. This product is intended for research and analytical applications. Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.

HY-123439

FTY720-C2	α-synuclein	Neurological Disease
FTY720-C2 is a derivative of FTY72 (HY-12005). FTY720-C2 promotes the expression of brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) in multiple system atrophy (MSA) models, without causing immunosuppression. FTY720-C2 improves motor dysfunction and reduces the levels of insoluble alpha-synuclein (αSyn) in MSA mouse models. FTY720-C2 is blood-brain barrier penetrate .

HY-182794

NLRP3-IN-89	NOD-like Receptor (NLR) Interleukin Related NF-κB	Neurological Disease
NLRP3-IN-89 is a NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. NLRP3-IN-89 inhibits the NLRP3 inflammasome pathway, reduces IL-1β secretion, and exhibits minimal interference with the NF-κB pathway. NLRP3-IN-89 can be used for the research of Parkinson's disease, frontotemporal dementia, multiple system atrophy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain injury .

HY-B1435R

Moxisylyte hydrochloride (Standard) Thymoxamine hydrochloride (Standard)	Adrenergic Receptor Reference Standards	Cardiovascular Disease Neurological Disease Metabolic Disease
Moxisylyte (Thymoxamine) hydrochloride Standard is the analytical standard of Moxisylyte hydrochloride (HY-B1435). This product is intended for research and analytical applications. Moxisylyte (Thymoxamine) hydrochloride is a selective α₁A-adrenergic receptor antagonist. Moxisylyte hydrochloride competitively antagonizes the activation mediated by norepinephrine. Moxisylyte hydrochloride relaxes penile cavernous smooth muscle and aids erectile function. Moxisylyte hydrochloride is applicable to research related to erectile dysfunction and multiple system atrophy.

Crocin II	Structural Classification Neurological Disease Classification of Application Fields Terpenoids Rubiaceae Diterpenoids Plants Gardenia jasminoides Ellis Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite α-synuclein
Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers .

Crocin II (Standard)	Structural Classification Terpenoids Rubiaceae Diterpenoids Plants Gardenia jasminoides Ellis Source Classification	Reference Standards Endogenous Metabolite α-synuclein
Crocin II (Standard) is the analytical standard of Crocin II. This product is intended for research and analytical applications. Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC₅₀ of 0.541 μM and a EC₅₀ of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

multiple system atrophy

Inhibitors & Agonists

NaturalProducts

Natural
Products